Truveta

Yesterday in CNN Health, Dr. Nina Masters from our Truveta Research team spoke to the importance of measles contact tracing – as an airborne pathogen, it's becoming increasingly difficult to identify when and where individuals are contracting the disease. She also emphasized the ongoing importance of vaccination as a way to limit the spread. For the latest insights on measles contact tracing, check out the full article: https://tr.vet/4261S0z

💉 😷 Since the measles vaccine was introduced in 1963, there had been a significant decline in cases. Following widespread adoption, measles cases dropped dramatically, leading to its elimination from the US in 2000. In the time since, measles remains one of the most contagious human diseases, and with its numbers rising in the US, we took a closer look at first and second-dose measles vaccination rates among children. Truveta Research found that first and second dose vaccination rates have dropped from 2020 to 2024. While the first dose of the measles vaccine is recommended between 12 to 15 months of age, second doses are recommended between 48 and 72 months of age. In order for the vaccine to be 97% effective against measles, children need both doses of the MMR or MMRV vaccine. Get the latest insights in our blogs: https://tr.vet/3Gda5qY | https://tr.vet/4lkVOJ9

With measles cases rising, Truveta Research set out to understand what’s happening with vaccination rates in children with data as recent as February 2025. Our new report shows vaccinations rates have continued to decline since 2020. Most childhood vaccination studies take years to complete. Ours took weeks. Here’s why: 📁 Analysis utilized shareable data definitions for MMR and MMRV 🛠️ Built using python code end-to-end in Truveta Studio 👀 Fully transparent code and analysis for other researchers to view Dive into the full study — including definitions and code — here: https://tr.vet/42lR3Gy

Happy #WorldHealthDay 🌎 📊 At Truveta, we're on a mission of Saving Lives with Data and we couldn't be more excited for our third annual Truveta Symposium where in three short weeks we will collaborate with our customers and members in life sciences, public health and healthcare to advance research with real-world data. Learn more about what's to come: https://tr.vet/3RjroJD

The latest respiratory virus monitoring report is here, with Truveta Data as recent as February 2025. Here's what we found: 📉 Respiratory virus-associated hospitalizations are down 🤧 Influenza continues to be the leading cause of these hospitalizations 🏥 RSV-related hospitalizations rose in children ages 4 and younger The good news: respiratory virus-related hospitalizations dropped from 9% of total hospitalizations in our last report to 6% in our latest. Learn more in the full report: https://tr.vet/4iQcMxr

Today, our general counsel Dave Heiner announced his retirement, and our deputy general counsel Simonne L. was promoted to general counsel at Truveta. We are so grateful to have their exceptional legal expertise to guide us here at Truveta. Dave was instrumental in building the legal foundation at Truveta and most recently inked our latest major initiative with the #TruvetaGenomeProject. We wish Dave the best in his non-profit adventures into retirement. We’re thrilled to celebrate Simonne joining our senior leadership team. Simonne’s leadership on commercial transactions, compliance requirements, and employment law is world class, and her principled approach and strong work ethic continue to stand out. Please join us in congratulating Dave and Simonne!

Our recent analysis featured in CNN reveals a concerning trend: only 68.5% of children received their first MMR vaccine dose by 15 months in 2024, down from 77% in 2020. This decline contributes to the ongoing measles outbreak, with over 500 cases reported this year. Dr. Nina Masters, Senior Research Scientist at Truveta, warns: “The pool of children at risk has grown since COVID. This is troubling.” With vaccination rates falling, especially in rural areas, rapid vaccination is crucial to control the outbreak and protect vulnerable communities. Read more: https://lnkd.in/gmQmYrs4

Measles is on the rise, so we took a closer look at vaccination rates for infants to find out what's changed in recent years. Here's what we found: 1️⃣ Average annual rate of measles vaccination for infants by 23 months dropped from 92.4% in 2020 to 84.9% in 2024 2️⃣ 75% of children in urban areas received one measles dose by 15 months, whereas only 65.5% of children in rural areas did 3️⃣ In 2024, the average measles vaccination rate for children by 13 months was 58.9%, and 68.5% for children by 15 months Read the full research report here: https://tr.vet/3YjAyth

Summer is quickly approaching, and Truveta has a packed schedule of events until then — we're excited to share our attendance at this year's ISPOR, ASCO, and DIA conferences. ISPOR 2025 🗓️ May 13-16 📍 Montreal, Quebec Join us at ISPOR 2025 (ISPOR—The Professional Society for Health Economics and Outcomes Research) — the world's leading conference for health economics and outcomes research. ASCO 2025 🗓️ May 31-June 2 📍 Chicago, Illinois Join us for the The American Society of Clinical Oncology (ASCO) conference: a hub for oncology leaders, researchers, and clinicians. DIA 2025 🗓️ June 16-18 📍 Chicago, Illinois Finally, join us for the Drug Information Association (DIA) conference, which brings together pharmaceutical, biotechnology, and regulatory experts. We hope to see you there!

💡 A new study from Olio Labs using Truveta Data showed that women experience greater side effects than men on GLP-1s, but also greater weight loss. Additional findings from their research include: 1️⃣ Women experience nausea and vomiting 2.5x more than men on GLP-1s 2️⃣ Higher estrogen levels in women correlate with more severe side effects 3️⃣ Women's heightened response is linked to differences in brain receptor expression and hormone fluctuations A possible solution? "Research suggests personalized dosing — adjusting medication based on menstrual cycle phases — could reduce side effects and discontinuation rates." Learn more: https://tr.vet/4lcEhmn